As doxorubicin and cisplatin are among the most popular chemotherapeutics in osteosarcoma [3, 35], we sought to investigate whether additional TOPK inhibition would enhance osteosarcoma chemosensitivity. This evidence concerns the gene PBK and osteosarcoma.